Ferrari, S.L.
Abrahamsen, B.
Napoli, N.
Akesson, K.
Chandran, M.
Eastell, R.
El-Hajj Fuleihan, G.
Josse, R.
Kendler, D.L.
Kraenzlin, M.
Suzuki, A.
Pierroz, D.D.
Schwartz, A.V.
Leslie, W.D.
Ferrari, S.L.
Abrahamsen, B.
Akesson, K.
Ardawi, M.S.M.
Chandran, M.
Cooper, C.
Eastell, R.
El-Hajj Fuleihan, G.
Josse, R.
Kendler, D.L.
Kraenzlin, M.
Leslie, W.D.
Mithal, A.
Napoli, N.
Suzuki, A.
Schwartz, A.V.
,
Article History
Received: 7 June 2018
Accepted: 19 July 2018
First Online: 31 July 2018
Compliance with ethical standards
:
: S Ferrari has received research grants, honoraria, and/or consultancies from Amgen, UCB, MSD, Labatec, Agnovos. B Abrahamsen has received research contracts with Novartis and UCB with funds paid to the institution. D Kendler has received research grants, honoraria, and/or consultancies from Amgen, Eli Lilly, AstraZeneca, Pfizer. R Eastell has received research grants from Alexion, Amgen Inc., and Ultragenyx, and consulting fees from Immunodiagnostic Systems, GlaxoSmithKline, and Amgen Inc. A Suzuki has received research grants and/or honoraria from Astellas, Chugai, Daiichi-Sankyo, Kyowa-Hakko Kirin, MSD, Novo Nordisk, Ono, Pfizer, Taisho Toyama, Tanabe-Mitsubishi and Takeda. R Josse has received consultancy fees and speaker honoraria from Amgen, Lilly, Merck. K Akesson has received lecture fees or consultancies from MSD, UCB, Amgen, Eli Lilly and Sandoz. A Schwartz has received a research grant from Hologic and consulting fees from Amgen. N Napoli has received consulting fees from Lilly and Amgen. G El-Hajj Fulehain, M Chandran, DD Pierroz, M Kraenzlin have no disclosure.